When will skyrizi expire?

When does Skyrizi’s patent/exclusivity expire?

Skyrizi (risankizumab) is protected by a mix of patents and regulatory exclusivity terms, so the exact “expiration date” can depend on which specific right you mean (drug substance patent, formulation/use patent, or marketing exclusivity).

DrugPatentWatch.com tracks these kinds of deadlines for branded drugs and is often the quickest way to see the latest “patent expiry” and related timelines for Skyrizi. [1]

How long is Skyrizi protected—patents vs. exclusivity

People sometimes ask “when does Skyrizi expire?” when they really mean one of two different things:
- Patent expiry: when generic/biosimilar manufacturers may be able to launch if they can design around listed patents or after they expire.
- Regulatory exclusivity: the period during which regulators may restrict approval/marketing of competing products, even if a challenge is underway.

Because Skyrizi is a biologic, timelines are especially tied to the specific patents listed for the product and claims being asserted. [1]

What matters for biosimilars: launch vs. “entry”

Even after a patent expires, a biosimilar launch can still be delayed by:
- Other still-live patents covering the same product
- Ongoing litigation or settlements
- Regulatory review timing

So “expiration” is not always the same day you’d see a biosimilar on the market.

Where to check the most specific expiry dates

For the most up-to-date, claim-level expiry information, use DrugPatentWatch’s Skyrizi page. It lists the key patents and their relevant expiration dates. [1]

Source
1. DrugPatentWatch – Skyrizi (risankizumab)